NASDAQ$CUE
Cue Biopharma Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Cue Biopharma reported a decrease in collaboration revenue and an increase in net loss for Q1 2025, while also detailing new strategic collaborations and a public offering.
Cue Biopharma, Inc. experienced a decrease in collaboration revenue and an increase in net loss for the first quarter of 2025 compared to the same period last year. The company reported a net loss of $12.257 million and collaboration revenue of $0.421 million. Despite the losses, the company secured significant funding through a public offering and a new collaboration agreement with Boehringer Ingelheim International GmbH, which are expected to fund operations into Q2 2026.
- Collaboration revenue decreased by $1.3 million to $0.421 million in Q1 2025, primarily due to the termination of the Ono Collaboration and Option Agreement.
- Net loss for Q1 2025 was $12.257 million, a slight decrease from $12.347 million in Q1 2024.
- Research and development expenses decreased by $1.7 million to $8.547 million, mainly due to lower clinical trial costs and employee compensation.
- The company secured approximately $18.0 million in net proceeds from a public offering and an upfront payment of $12.0 million from a new collaboration agreement with Boehringer Ingelheim International GmbH in April 2025, extending its cash runway into Q2 2026.
Headline financials
Revenue & EPS history
Cue Biopharma · Revenue · Quarterly
$421K
Revenue by segment
Cue Biopharma · $5.69M total across 1 segment · Q1 2026
- Collaboration revenue$5.69M—100.0%
Forward guidance
Cue Biopharma anticipates increased expenses due to ongoing research and development, new clinical trials, and operating as a public company. The company expects to finance future cash needs through equity offerings, collaborations, and strategic alliances, but acknowledges substantial doubt about its ability to continue as a going concern without additional funding.
Tailwinds
- Continued preclinical development of CUE-401 and CUE-500 series (excluding CUE-501, which has been licensed to BI).
- Assessment of maturing clinical data for CUE-100 series (CUE-101 and CUE-102).
- Leveraging programs, including autoimmune programs, to advance drug product candidates into preclinical and clinical development.
- Seeking regulatory approvals for successful clinical trials.
- Establishing sales, marketing, medical affairs, and distribution infrastructure for commercialization.
Headwinds
- Need to raise additional capital to fund future operations and remain a going concern.
- Volatility in capital markets and general economic conditions may hinder fundraising efforts.
- Potential requirement to delay, reduce, or eliminate product development or commercialization efforts if unable to raise sufficient funds.
- Risk of dilution to current stockholders if additional capital is raised through equity offerings.
- Potential for new investors to demand rights, preferences, or privileges senior to existing common stockholders.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-0.1%
Avg return
Earnings day
-1.2%
Avg return
5 days after
+1.3%
Avg return
30 days after
45%
15 / 33 earnings
Positive
+25.2%
Q4 2021
Best reaction
-16.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -14.2% | -31.0% | — | |
| Q4 2025 | -0.3% | -14.7% | +97.1% | |
| Q3 2025 | -8.5% | -13.2% | -27.1% | |
| Q2 2025 | +0.0% | +3.7% | -6.1% | |
| Q1 2025 | -3.5% | -2.5% | -18.6% | |
| Q4 2024 | +3.3% | -2.4% | -9.4% | |
| Q3 2024 | -16.7% | -28.0% | -37.3% | |
| Q2 2024 | -6.3% | +19.9% | -7.1% | |
| Q1 2024 | -8.9% | -18.8% | -22.5% | |
| Q4 2023 | +2.7% | -5.4% | +3.2% | |
| Q3 2023 | +14.9% | +5.4% | +8.1% | |
| Q2 2023 | -12.3% | -14.2% | -26.5% | |
| Q1 2023 | -3.7% | -12.4% | -23.2% | |
| Q4 2022 | +7.1% | +7.4% | +14.2% | |
| Q3 2022 | +20.4% | +2.5% | -6.1% | |
| Q2 2022 | +1.7% | -5.7% | +3.3% | |
| Q1 2022 | -11.0% | -10.0% | -8.5% | |
| Q4 2021 | +25.2% | +27.2% | +2.9% | |
| Q3 2021 | -0.4% | +6.4% | +4.1% | |
| Q2 2021 | +7.7% | +3.5% | +23.1% | |
| Q1 2021 | -1.4% | +2.4% | -4.2% | |
| Q4 2020 | -7.5% | -4.5% | -14.3% | |
| Q3 2020 | +11.2% | +7.1% | +17.3% | |
| Q2 2020 | +1.3% | +2.5% | -16.0% | |
| Q1 2020 | +8.3% | +13.3% | -4.4% | |
| Q4 2019 | -15.5% | +4.8% | +59.8% | |
| Q3 2019 | -2.0% | -1.8% | +38.4% | |
| Q2 2019 | +1.3% | +7.5% | +6.4% | |
| Q1 2019 | +0.1% | +1.5% | -6.7% | |
| Q4 2018 | +9.7% | +23.8% | +20.3% | |
| Q3 2018 | -6.7% | -8.8% | -16.2% | |
| Q2 2018 | -0.7% | -4.9% | +11.3% | |
| Q4 2017 | +0.5% | +1.2% | -13.5% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro